Trastuzumab emtansine - Immunogen/Roche

Drug Profile

Trastuzumab emtansine - Immunogen/Roche

Alternative Names: Ado-trastuzumab emtansine; DM1-trastuzumab immunoconjugate; Kadcyla; PRO-132365; R3502; RG 3502; RO 5304020; T-DM1; Trastuzumab-DM1; Trastuzumab-DM1 immunoconjugate; Trastuzumab-MCC-DM1; Trastuzumab-MCC-DM1 antibody-drug conjugate; Trastuzumab–SMCC–DM1 conjugate

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; ImmunoGen
  • Developer Chugai Pharmaceutical; Genentech; Memorial Sloan-Kettering Cancer Center; Roche; University College London; University of Miami
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Macrolides; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer
  • Phase II/III Gastric cancer
  • Phase II Bladder cancer; Lung cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer

Most Recent Events

  • 27 Sep 2018 Roche completes a phase I trial in Breast cancer in China (NCT03153163)
  • 26 Jul 2018 Roche completes a phase II trial in Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater) in USA, Spain, Germany, Switzerland, South Korea, Poland, Italy (IV) (EudraCT2014-001237-83) (NCT02289833)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top